Mason Carrico
Stock Analyst at Stephens & Co.
(3.88)
# 615
Out of 5,090 analysts
77
Total ratings
50.75%
Success rate
10.92%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $244.55 | -3.91% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $2.39 | -16.32% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $74.97 | +1.37% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $11.90 | -7.56% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $36.23 | +84.93% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $128.96 | -18.58% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $17.77 | -21.22% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $18.53 | +115.87% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $108.51 | +5.98% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $44.61 | +0.87% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $102.02 | -46.09% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.99 | +20.24% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $25.38 | -33.02% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $70.79 | -26.54% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $7.09 | +182.09% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $38.65 | +6.08% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $244.55
Upside: -3.91%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $2.39
Upside: -16.32%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $74.97
Upside: +1.37%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $11.90
Upside: -7.56%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $36.23
Upside: +84.93%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $128.96
Upside: -18.58%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $17.77
Upside: -21.22%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $18.53
Upside: +115.87%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $108.51
Upside: +5.98%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $44.61
Upside: +0.87%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $102.02
Upside: -46.09%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.99
Upside: +20.24%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $25.38
Upside: -33.02%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $70.79
Upside: -26.54%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $7.09
Upside: +182.09%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $38.65
Upside: +6.08%